The company’s shares closed last Friday at $1.05, close to its 52-week low of $0.95.
Currently, the analyst consensus on Cogstate Ltd is a Moderate Buy with an average price target of $1.64.
See today’s best-performing stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cogstate Ltd is a cognitive science company. The principal activity of the company is a sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In clinical trials segment, technology and services are sold to pharmaceutical, biotechnology, nutraceutical, and functional food companies.
Read More on COGZF:
- Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (OtherRMSYF) and Paradigm Biopharmaceuticals Ltd. (OtherPBIGF)
- Jarden Reaffirms Their Buy Rating on Star Entertainment Group Limited (EHGRF)
- Austal Limited (AUTLF) Gets a Buy Rating from Citigroup
- Citigroup Believes Bank of Queensland Limited (BKQNF) Won’t Stop Here
- Origin Energy Limited (OGFGF) Receives a Sell from Jarden
